Search the Newsreel

TG Therapeutics, Inc. Q2 2026 Earnings Call Summary

Does Federal Agricultural Mortgage's (AGM) EPS Surge Reflect Deeper, Sustainable Efficiency Gains?

Angel Oak Mortgage REIT Inc. (NYSE:AOMR) Plans Quarterly Dividend of $0.32

Angel Oak Mortgage REIT's (AOMR) Buy Rating Reiterated at JonesTrading

Angel Oak Mortgage REIT (NYSE:AOMR) Posts Earnings Results, Beats Expectations By $0.02 EPS

360 Capital Mortgage REIT (ASX: TCF) Share Price Update: Key Trading Metrics for 4 August 2026

Why Did MCAN Mortgage Corporation (TSX:MKP) Stock Drop 5.60% on 31 July 2026?

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

TG Therapeutics announced strong second-quarter 2026 financial results, with total global revenue reaching approximately $240 million and U.S. BRIUMVI® net product revenue at $228 million. The company has raised its full-year 2026 revenue guidance for both total global revenue to $950 million and U.S. …

TG Therapeutics (TGTX) Is Down 15.9% After Q2 Miss But Raised 2026 Outlook - What's Changed

TG Therapeutics (TGTX) reported a Q2 2026 revenue increase but missed EPS estimates, leading to a 15.9% stock drop. Despite this, the company raised its 2026 global revenue outlook to about US$950 million, driven by confidence in Briumvi's momentum and its broader pipeline. Investors …

Why Sweetgreen Stock Fell 27% in July

Key Points Sweetgreen stock plunged on news of a lettuce-related cyclospora outbreak. The company was not directly connected to the outbreak. Thursday's earnings report could be a turning point for Sweetgreen.10 stocks we like better than Sweetgreen › Shares of Sweetgreen (NYSE: SG) fell …

Granite Point refinances CRE CLO assets, cuts funding costs By Investing.com

Granite Point Mortgage Trust Inc. (NYSE:GPMT) has refinanced assets from its two remaining commercial real estate collateralized loan obligations (CRE CLOs) onto its JPMorgan Chase Bank repurchase facility. This strategic move, which involved extending the facility to July 2028 and increasing it to $651 …

Granite Point Mortgage Trust (NYSE: GPMT) extends $651M JPMorgan repurchase facility

Granite Point Mortgage Trust (NYSE: GPMT) has extended its $651 million JPMorgan repurchase facility. The amendments increase the maximum facility amount, extend its maturity to July 28, 2028, and adjust financial covenants related to "Unrestricted Cash" and "Minimum Tangible Net Worth." This uncommitted facility …

TG Therapeutics (TGTX) Stock Sinks As Profit Shrinks Behind BRIUMVI Growth

TG Therapeutics (TGTX) stock dropped 11% after earnings, despite strong revenue growth from its multiple sclerosis drug, BRIUMVI. The company's profit shrank significantly due to heavy manufacturing-related charges, raising concerns about margin pressure and reliance on BRIUMVI. This performance has fueled arguments from bears …

Kaplan Fox Deadline Alert: BitGo Holdings, Inc. (NYSE: BTGO) Investors Have Until August 7, 2026 to Seek a Lead Plaintiff Role

Kaplan Fox & Kilsheimer LLP announced a class action lawsuit against BitGo Holdings, Inc. (NYSE: BTGO) for investors who purchased stock in or traceable to its January 22, 2026 IPO, or BitGo securities between January 22, 2026, and May 13, 2026. The lawsuit alleges …

BTGO Deadline: BTGO Investors with Losses in Excess of $100K Have Opportunity to Lead BitGo Holdings, Inc. Securities Lawsuit

The Rosen Law Firm reminds investors of BitGo Holdings, Inc. (NYSE: BTGO) that the lead plaintiff deadline for a securities class action lawsuit is August 7, 2026. The lawsuit alleges that BitGo's IPO Offering Documents contained misleading statements and that the company failed to …

Granite Point Mortgage Trust Inc. expected to post a loss of 39 cents a share - Earnings Preview

Granite Point Mortgage Trust Inc. (GPMT) is anticipated to report a loss of 39 cents per share in its upcoming earnings. This forecast is based on information from Refinitiv. The article provides a brief earnings preview for the company.

TG Therapeutics (NASDAQ:TGTX) Falls as Q2 Revenue Beats but EPS Misses, Guidance Raised Below Estimates

TG Therapeutics (TGTX) reported mixed Q2 2026 financial results, with total global revenue exceeding consensus estimates but non-GAAP earnings per share significantly missing expectations. The company also raised its full-year guidance, though it still fell slightly below analyst projections, leading to a negative reaction …

BITGO HOLDINGS DEADLINE FRIDAY AUGUST 7th: Bragar Eagel & Squire, P.C. Urges BitGo Holdings, Inc. Investors with Large Losses to Contact the Firm Before the Lead Plaintiff Deadline

Bragar Eagel & Squire, P.C. has filed a class action lawsuit against BitGo Holdings, Inc. (NYSE:BTGO) on behalf of investors who purchased shares during its initial public offering on January 22, 2026, or between January 22, 2025, and May 13, 2026. The lawsuit alleges …

Three Noteworthy Biotechs Just Reported Earnings — And Only One Recovered

Top-notch biotech stocks TG Therapeutics and Twist Bioscience diverged Monday on mixed earnings reports. Continue Reading

Cherry Hill Mortgage Investment Corporation Sets Date for Second Quarter 2026 Earnings Release and Conference Call

TG Therapeutics down 11% following Q2 bottom line miss

[Second Quarter Q2 Profits Stock Trading Chart 3D Background] filo * TG Therapeutics is down ~11% in Monday trading after reporting Q2 EPS that missed expectations. * Diluted EPS of $0.05 compares to $0.17 in the year-ago period. * Although TG was helped in …

TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down

TG Therapeutics TGTX reported earnings of 5 cents per share for the second quarter of 2026, missing the Zacks Consensus Estimate of 41 cents. The company had reported earnings of 17 cents per share in the year-ago quarter. Total revenues in the second quarter …

BTGO INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of the August 7, 2026 Lead Plaintiff Deadline in the BitGo Holdings, Inc. Securities Class Action

Holzer & Holzer, LLC has filed a shareholder class action lawsuit against BitGo Holdings, Inc. (NYSE: BTGO) alleging that the company's IPO offering documents contained false and misleading statements, specifically regarding the risks of declining digital asset prices on BitGo's financial performance. Investors who …

BTGO Investors Have Opportunity to Lead BitGo Holdings, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against BitGo Holdings, Inc. (NYSE: BTGO) for alleged securities fraud, encouraging investors who purchased shares during the specified class period to seek lead plaintiff appointment. The lawsuit claims BitGo made false and …

Why This Top-Notch Trio Of Biotech Stocks Just Took A Tumble

Top-notch biotech stocks TG Therapeutics and Twist Bioscience took a tumble Monday on mixed second-quarter reports. Continue Reading

Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 Earnings

TG Therapeutics (TGTX) reported $240.34 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 70.3%. EPS of $0.05 for the same period compares to $0.17 a year ago. The reported revenue represents a surprise of +4.08% over the Zacks …

Federal Agricultural Mortgage Corp stock hits all-time high at 231.9 USD

Federal Agricultural Mortgage Corp (Farmer Mac) stock has reached an all-time high of $231.9, demonstrating significant growth with a 38.47% increase over the past year and 36.56% in the last six months. InvestingPro analysis suggests the stock is currently undervalued and highlights the company's …

Tredegar's Next Financial Update Is Planned for Aug. 7, 2026

Tredegar Corporation (NYSE: TG) announced its plan to release financial results for the second quarter of 2026 on August 7, 2026. The company is an industrial manufacturer with two main businesses: custom aluminum extrusions and surface protection films. Tredegar operates manufacturing facilities in North …

RBC Capital Adjusts EastGroup Properties Price Target to $220 From $208, Maintains Sector Perform Rating

RBC Capital has increased its price target for EastGroup Properties (EGP) to $220 from $208, while maintaining a "Sector Perform" rating. This adjustment follows recent activities for EastGroup Properties, including a previous price target adjustment by Truist Securities and various financial updates such as …

Granite Point Mortgage Trust Inc. Announces Refinance of Legacy CLO Assets, Extension and Upsize of JPMorgan Repurchase Facility

NEW YORK, August 03, 2026--(BUSINESS WIRE)--Granite Point Mortgage Trust Inc. (NYSE: GPMT) ("GPMT," "Granite Point" or the "Company") today announced that it refinanced the assets that had been financed in its two remaining CRE CLOs, GPMT 2021-FL3 and GPMT 2021-FL4, on its JPMorgan Chase …

TGS ASA's Dividend Analysis

This article first appeared on GuruFocus. Assessing the Sustainability of TGS ASA's Upcoming Dividend Payment TGS ASA (TGSGY) recently announced a total dividend of $0.16 per share, with the ex-dividend date set for 2026-08-03. This payment includes a $0.16 per share cash dividend payable …

TG Therapeutics (NASDAQ: TGTX) lifts 2026 BRIUMVI revenue outlook

TG Therapeutics, Inc. (NASDAQ: TGTX) generated $616.29 million USD in revenue last year. The primary source of this revenue, $616.29 million USD, came from its "Novel Treatments for B-cell Diseases" segment, an increase from $329.00 million USD the previous year. All reported revenue originated …

BTGO Stockholders Have Opportunity to Lead BitGo Holdings, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against BitGo Holdings, Inc. (NYSE:BTGO) and its officers, alleging violations of federal securities laws. The lawsuit claims that the company's IPO documents were negligently prepared and that false and misleading statements were made …

TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss

TG Therapeutics has raised its full-year 2026 revenue guidance, projecting that its multiple sclerosis drug, Briumvi, is on track to achieve an annualized U.S. revenue run rate of approximately $1 billion. This update follows a strong Q2 performance where global revenue increased by 70%, …

Invesco Mortgage Capital adds director with 30-plus years of finance experience

Keefe, Bruyette & Woods Issues Positive Forecast for Federal Agricultural Mortgage (NYSE:AGM) Stock Price